Cargando…
Differential Activation of Lymphokine‐activated Killer Cells with Different Surface Phenotypes by Cultivation with Recombinant Interleukin 2 or T‐cell Growth Factor in Gastric Cancer Patients
Fourteen days' culture of human peripheral blood lymphocytes (PBL) with recombinant interleukin 2 (rIL 2) or T cell growth factor (TCGF) results in the generation of lymphoklne‐activated killer (LAK) effector cells which have the unique property of lysing natural killer (NK)‐resistant human tum...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
1989
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917700/ https://www.ncbi.nlm.nih.gov/pubmed/2498249 http://dx.doi.org/10.1111/j.1349-7006.1989.tb02283.x |
_version_ | 1783317269106917376 |
---|---|
author | Koyama, Shohei Ebihara, Tsugio Fukao, Katashi Osuga, Toshiaki |
author_facet | Koyama, Shohei Ebihara, Tsugio Fukao, Katashi Osuga, Toshiaki |
author_sort | Koyama, Shohei |
collection | PubMed |
description | Fourteen days' culture of human peripheral blood lymphocytes (PBL) with recombinant interleukin 2 (rIL 2) or T cell growth factor (TCGF) results in the generation of lymphoklne‐activated killer (LAK) effector cells which have the unique property of lysing natural killer (NK)‐resistant human tumor cells, Daudi, as well as NK‐sensitive, K562 cells. LAK cells were generated from both normal and gastric cancer patients' PBL. However, LAK cell activities induced by rIL 2 or TCGF decreased with the progress of the tumor growth. In addition, TCGF‐induced LAK cell activities were found to be lower than the rIL 2‐indnced LAK cell activities. Different mechanisms may be involved in the decreases of the rIL 2‐induced and TCGF‐induced LAK cell activities. This study further demonstrates that the cell types involved are also heterogeneous, as determined by phenotypic characteristics. The LAK‐effector cell type was analyzed by two‐color flow cytometry. RIL 2‐induced LAK cells showed increased proportions of CD4(±)Leu 8(‐) and Leu 7(±)CD16(‐), and a decreased proportion of CD8(±)CD11(‐) cells, which are believed to be associated with killer T cell functions. In contrast, TCGF‐induced LAK cells revealed significantly increased proportions of CD8(±)CD11(‐)and CD4(±)Leu 8(‐) cells, and a decreased proportion of Leu 7(±)CD16(‐) cells. Thus, LAK cells with different surface phenotypes were induced by the cultivations with rIL 2 and with TCGF. |
format | Online Article Text |
id | pubmed-5917700 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1989 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-59177002018-05-11 Differential Activation of Lymphokine‐activated Killer Cells with Different Surface Phenotypes by Cultivation with Recombinant Interleukin 2 or T‐cell Growth Factor in Gastric Cancer Patients Koyama, Shohei Ebihara, Tsugio Fukao, Katashi Osuga, Toshiaki Jpn J Cancer Res Article Fourteen days' culture of human peripheral blood lymphocytes (PBL) with recombinant interleukin 2 (rIL 2) or T cell growth factor (TCGF) results in the generation of lymphoklne‐activated killer (LAK) effector cells which have the unique property of lysing natural killer (NK)‐resistant human tumor cells, Daudi, as well as NK‐sensitive, K562 cells. LAK cells were generated from both normal and gastric cancer patients' PBL. However, LAK cell activities induced by rIL 2 or TCGF decreased with the progress of the tumor growth. In addition, TCGF‐induced LAK cell activities were found to be lower than the rIL 2‐indnced LAK cell activities. Different mechanisms may be involved in the decreases of the rIL 2‐induced and TCGF‐induced LAK cell activities. This study further demonstrates that the cell types involved are also heterogeneous, as determined by phenotypic characteristics. The LAK‐effector cell type was analyzed by two‐color flow cytometry. RIL 2‐induced LAK cells showed increased proportions of CD4(±)Leu 8(‐) and Leu 7(±)CD16(‐), and a decreased proportion of CD8(±)CD11(‐) cells, which are believed to be associated with killer T cell functions. In contrast, TCGF‐induced LAK cells revealed significantly increased proportions of CD8(±)CD11(‐)and CD4(±)Leu 8(‐) cells, and a decreased proportion of Leu 7(±)CD16(‐) cells. Thus, LAK cells with different surface phenotypes were induced by the cultivations with rIL 2 and with TCGF. Blackwell Publishing Ltd 1989-02 /pmc/articles/PMC5917700/ /pubmed/2498249 http://dx.doi.org/10.1111/j.1349-7006.1989.tb02283.x Text en |
spellingShingle | Article Koyama, Shohei Ebihara, Tsugio Fukao, Katashi Osuga, Toshiaki Differential Activation of Lymphokine‐activated Killer Cells with Different Surface Phenotypes by Cultivation with Recombinant Interleukin 2 or T‐cell Growth Factor in Gastric Cancer Patients |
title | Differential Activation of Lymphokine‐activated Killer Cells with Different Surface Phenotypes by Cultivation with Recombinant Interleukin 2 or T‐cell Growth Factor in Gastric Cancer Patients |
title_full | Differential Activation of Lymphokine‐activated Killer Cells with Different Surface Phenotypes by Cultivation with Recombinant Interleukin 2 or T‐cell Growth Factor in Gastric Cancer Patients |
title_fullStr | Differential Activation of Lymphokine‐activated Killer Cells with Different Surface Phenotypes by Cultivation with Recombinant Interleukin 2 or T‐cell Growth Factor in Gastric Cancer Patients |
title_full_unstemmed | Differential Activation of Lymphokine‐activated Killer Cells with Different Surface Phenotypes by Cultivation with Recombinant Interleukin 2 or T‐cell Growth Factor in Gastric Cancer Patients |
title_short | Differential Activation of Lymphokine‐activated Killer Cells with Different Surface Phenotypes by Cultivation with Recombinant Interleukin 2 or T‐cell Growth Factor in Gastric Cancer Patients |
title_sort | differential activation of lymphokine‐activated killer cells with different surface phenotypes by cultivation with recombinant interleukin 2 or t‐cell growth factor in gastric cancer patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917700/ https://www.ncbi.nlm.nih.gov/pubmed/2498249 http://dx.doi.org/10.1111/j.1349-7006.1989.tb02283.x |
work_keys_str_mv | AT koyamashohei differentialactivationoflymphokineactivatedkillercellswithdifferentsurfacephenotypesbycultivationwithrecombinantinterleukin2ortcellgrowthfactoringastriccancerpatients AT ebiharatsugio differentialactivationoflymphokineactivatedkillercellswithdifferentsurfacephenotypesbycultivationwithrecombinantinterleukin2ortcellgrowthfactoringastriccancerpatients AT fukaokatashi differentialactivationoflymphokineactivatedkillercellswithdifferentsurfacephenotypesbycultivationwithrecombinantinterleukin2ortcellgrowthfactoringastriccancerpatients AT osugatoshiaki differentialactivationoflymphokineactivatedkillercellswithdifferentsurfacephenotypesbycultivationwithrecombinantinterleukin2ortcellgrowthfactoringastriccancerpatients |